H.C. Wainwright raised the firm’s price target on Harpoon Therapeutics to $7.50 from $4.50 and keeps a Buy rating on the shares. The analyst updated the company’s model to reflect complete ownership of the HPN217 program and the recent 1 for 10 reverse split of common shares effective September 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HARP:
- Harpoon: AbbVie will not exercise HPN217 license option of prior deal
- Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
- Biotech Alert: Searches spiking for these stocks today
- Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
- Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023